Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Leases (2021 - 2025)

Indivior Pharmaceuticals has reported Operating Leases over the past 5 years, most recently at $32.0 million for Q4 2025.

  • Quarterly results put Operating Leases at $32.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $32.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $32.0 million, changed 0.0%.
  • Operating Leases for Q4 2025 was $32.0 million at Indivior Pharmaceuticals, up from $24.0 million in the prior quarter.
  • Over the last five years, Operating Leases for INDV hit a ceiling of $37.0 million in Q4 2022 and a floor of $24.0 million in Q3 2025.
  • Median Operating Leases over the past 5 years was $32.0 million (2024), compared with a mean of $31.8 million.
  • Biggest five-year swings in Operating Leases: increased 2.78% in 2022 and later fell 8.11% in 2023.
  • Indivior Pharmaceuticals' Operating Leases stood at $36.0 million in 2021, then grew by 2.78% to $37.0 million in 2022, then dropped by 8.11% to $34.0 million in 2023, then decreased by 5.88% to $32.0 million in 2024, then changed by 0.0% to $32.0 million in 2025.
  • The last three reported values for Operating Leases were $32.0 million (Q4 2025), $24.0 million (Q3 2025), and $29.0 million (Q2 2025) per Business Quant data.